Automated chemotherapy market seen reaching $2.04 billion by 2030

The Business Research Company says the automated chemotherapy preparation and infusion market will grow from $1.48 billion in 2026 to $2.04 billion by 2030, driven by cancer prevalence, safer drug handling and wider use of robotic pharmacy systems. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Automated chemotherapy systems aim to reduce dosing errors, limit staff exposure to toxic drugs and streamline oncology workflows. - The market outlook points to stronger demand for safer, more precise cancer treatment infrastructure as case volumes rise worldwide.

What happened: - The Business Research Company projected the automated chemotherapy preparation and infusion market to reach $2.04 billion by 2030. - The forecast implies an 8.3% compound annual growth rate from 2026 through 2030. - The market was estimated at $1.37 billion in 2025 and $1.48 billion in 2026. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period. - The report was released Sept. 15, 2026. - Download a free sample of the market report. - View the full market report.

The details: - Automated chemotherapy preparation and infusion uses robotic systems and closed-system transfer software in oncology pharmacies. - The systems automate liquid handling, dilution and labeling under sterile conditions. - The technology also supports inventory management and reduces direct exposure for pharmacy staff. - Historical growth was tied to rising global cancer prevalence, automation in hospital pharmacies, demand for precise chemotherapy dosing, expanding oncology treatment facilities and greater awareness of safe handling of hazardous drugs. - Expected growth drivers include precision oncology workflows, investment in automated pharmacy infrastructure, personalized chemotherapy, outpatient cancer care and stricter rules on medication traceability and safety. - The report highlights rising use of robotic chemotherapy compounding devices. - The report also cites growing demand for closed-system drug preparation technologies, fewer medication errors, broader sterile automation and stronger occupational safety measures. - The World Health Organization reported about 20.6 million new cancer cases globally in July 2026 and nearly 10 million deaths in the same year. - WHO projections indicate annual cancer cases could approach 35 million by 2050. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future-trend analysis, and updated graphics and tables.

Between the lines: - The forecast reflects a broader oncology shift toward automation, traceability and lower exposure risk in pharmacy operations. - Faster growth in Asia-Pacific suggests expanding cancer care investment and pharmacy modernization outside the market’s current center of gravity. - The inclusion of TAM tools and forecasting dashboards signals a report aimed at buyers, investors and strategy teams, not only clinical readers.

What's next: - Adoption will likely track cancer incidence, hospital pharmacy modernization and spending on automated compounding infrastructure. - Regulatory pressure on medication safety and traceability could further support deployment of these systems. - Personalized and outpatient cancer treatment models may expand the addressable market through 2030.

The bottom line: - Automated chemotherapy preparation and infusion is moving from niche infrastructure to a bigger part of oncology operations, with growth tied to safety, precision and rising cancer demand.